[
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=0aa108f5bffd9236c5c33f77f85b520ae3d80d4facadbe20e3b9147e78cba362",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733761860,
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "id": 131933287,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=0aa108f5bffd9236c5c33f77f85b520ae3d80d4facadbe20e3b9147e78cba362"
    }
  },
  {
    "ts": null,
    "headline": "Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.",
    "summary": "Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.",
    "url": "https://finnhub.io/api/news?id=67e4b587085932d0da27c0935c5158be47a17c8801999b47fbcd7b915e621473",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733759435,
      "headline": "Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.",
      "id": 131870703,
      "image": "https://media.zenfs.com/en/ibd.com/ca99382a9495e01f5703b092aadd1604",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.",
      "url": "https://finnhub.io/api/news?id=67e4b587085932d0da27c0935c5158be47a17c8801999b47fbcd7b915e621473"
    }
  },
  {
    "ts": null,
    "headline": "GSK Gets Positive Results in Blood-Cancer Drug Trial",
    "summary": "GSK Gets Positive Results in Blood-Cancer Drug Trial",
    "url": "https://finnhub.io/api/news?id=c5aa47f925ed3df50b878796631a629049cee4895a9567a956af93f74df6995e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733751900,
      "headline": "GSK Gets Positive Results in Blood-Cancer Drug Trial",
      "id": 131874318,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "GSK Gets Positive Results in Blood-Cancer Drug Trial",
      "url": "https://finnhub.io/api/news?id=c5aa47f925ed3df50b878796631a629049cee4895a9567a956af93f74df6995e"
    }
  },
  {
    "ts": null,
    "headline": "Institutional investors may adopt severe steps after Johnson & Johnson's (NYSE:JNJ) latest 3.5% drop adds to a year losses",
    "summary": "Key Insights Given the large stake in the stock by institutions, Johnson & Johnson's stock price might be vulnerable to...",
    "url": "https://finnhub.io/api/news?id=5bde6de749ea94b384fccb84c37198e5db7bdc2599ce838aaddf8dcb789ea125",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733749213,
      "headline": "Institutional investors may adopt severe steps after Johnson & Johnson's (NYSE:JNJ) latest 3.5% drop adds to a year losses",
      "id": 131870051,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Johnson & Johnson's stock price might be vulnerable to...",
      "url": "https://finnhub.io/api/news?id=5bde6de749ea94b384fccb84c37198e5db7bdc2599ce838aaddf8dcb789ea125"
    }
  },
  {
    "ts": null,
    "headline": "Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today findings from several online abstracts and posters on patients living with warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening condition where autoantibodies lead to the premature destruction of red blood cells, at the 2024 American Society of Hematology (ASH) Annual Meeting. These findings underscore the significant disease burden for the estimated one in 8,000 people living with wAIHA, including the high unmet need for targeted thera",
    "url": "https://finnhub.io/api/news?id=3490fd2933d1f7a596b2fd15a2a529ff03bdb6ba43a21c4ec07905f33d019fc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733749200,
      "headline": "Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options",
      "id": 131870052,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today findings from several online abstracts and posters on patients living with warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening condition where autoantibodies lead to the premature destruction of red blood cells, at the 2024 American Society of Hematology (ASH) Annual Meeting. These findings underscore the significant disease burden for the estimated one in 8,000 people living with wAIHA, including the high unmet need for targeted thera",
      "url": "https://finnhub.io/api/news?id=3490fd2933d1f7a596b2fd15a2a529ff03bdb6ba43a21c4ec07905f33d019fc5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Says 2 Studies of Potential Early Multiple Myeloma Drug Showed 'Promising' Efficacy",
    "summary": "Johnson & Johnson (JNJ) said Sunday that data from two investigational studies of its drug Tecvayli",
    "url": "https://finnhub.io/api/news?id=847d6a0fc9dab60c8b3b5ea49f35d0e2a8a34f1be4df8fdb56a86010baac7ffd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733743856,
      "headline": "Johnson & Johnson Says 2 Studies of Potential Early Multiple Myeloma Drug Showed 'Promising' Efficacy",
      "id": 131870053,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Sunday that data from two investigational studies of its drug Tecvayli",
      "url": "https://finnhub.io/api/news?id=847d6a0fc9dab60c8b3b5ea49f35d0e2a8a34f1be4df8fdb56a86010baac7ffd"
    }
  },
  {
    "ts": null,
    "headline": "J&J: studies the potential of nipocalamib in anemia",
    "summary": "Johnson & Johnson presented the results of several studies on warm autoimmune hemolytic anemia at the 2024 annual meeting of the American Society of Hematology.Affecting around one in 8,000 people,...",
    "url": "https://finnhub.io/api/news?id=72519039d37de89693f5a1bb6e7e03d0a5cacabd731d36071dab0705bd667bca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733737455,
      "headline": "J&J: studies the potential of nipocalamib in anemia",
      "id": 131869576,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson presented the results of several studies on warm autoimmune hemolytic anemia at the 2024 annual meeting of the American Society of Hematology.Affecting around one in 8,000 people,...",
      "url": "https://finnhub.io/api/news?id=72519039d37de89693f5a1bb6e7e03d0a5cacabd731d36071dab0705bd667bca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma",
    "summary": "SAN DIEGO - Johnson & Johnson today announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance...",
    "url": "https://finnhub.io/api/news?id=d6300d4471f939a5303d2426497e6f62c928f7a5f12738f785b7b9dbdeda6083",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733736504,
      "headline": "Johnson & Johnson - TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma",
      "id": 131869391,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SAN DIEGO - Johnson & Johnson today announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance...",
      "url": "https://finnhub.io/api/news?id=d6300d4471f939a5303d2426497e6f62c928f7a5f12738f785b7b9dbdeda6083"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - DARZALEX FASPRO -based regimens demonstrate improved rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma",
    "summary": "SAN DIEGO - Johnson & Johnson today announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free...",
    "url": "https://finnhub.io/api/news?id=0e8ed70516c0ce50e9347f2eb400a29f06e50105860369f3ab316df85a744873",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733736377,
      "headline": "Johnson & Johnson - DARZALEX FASPRO -based regimens demonstrate improved rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma",
      "id": 131869365,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SAN DIEGO - Johnson & Johnson today announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free...",
      "url": "https://finnhub.io/api/news?id=0e8ed70516c0ce50e9347f2eb400a29f06e50105860369f3ab316df85a744873"
    }
  },
  {
    "ts": null,
    "headline": "J&J: promising data for Tecvayli in myeloma",
    "summary": "Johnson & Johnson announces promising data on Tecvayli from two studies , presented at ASH 2024. These trials explore the use of Tecvayli in patients with newly diagnosed multiple myeloma , and...",
    "url": "https://finnhub.io/api/news?id=6938c25f068e7d8567fd61118ca856e86214655ebf99f13e5c3bf341beb85d7e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733727378,
      "headline": "J&J: promising data for Tecvayli in myeloma",
      "id": 131867687,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces promising data on Tecvayli from two studies , presented at ASH 2024. These trials explore the use of Tecvayli in patients with newly diagnosed multiple myeloma , and...",
      "url": "https://finnhub.io/api/news?id=6938c25f068e7d8567fd61118ca856e86214655ebf99f13e5c3bf341beb85d7e"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive data in multiple myeloma",
    "summary": "Johnson & Johnson announces that a Phase 3 study demonstrated that Darzalex Faspro significantly delayed the progression of high-risk indolent multiple myeloma to active multiple myeloma , while...",
    "url": "https://finnhub.io/api/news?id=26e30a9cbf9c8161816c26438906afb6594f31fc5280085cb0864df4be9c1cc8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733726648,
      "headline": "J&J: positive data in multiple myeloma",
      "id": 131867606,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that a Phase 3 study demonstrated that Darzalex Faspro significantly delayed the progression of high-risk indolent multiple myeloma to active multiple myeloma , while...",
      "url": "https://finnhub.io/api/news?id=26e30a9cbf9c8161816c26438906afb6594f31fc5280085cb0864df4be9c1cc8"
    }
  },
  {
    "ts": null,
    "headline": "Apple Tops the List of Best-Managed Companies of 2024",
    "summary": "Tech companies hold six of the top 10 spots, while Mastercard jumped to fifth place from 24th last year.",
    "url": "https://finnhub.io/api/news?id=d13cca814be7a6fe4ddcc7139ff6790f37d3900f98cf04b25ea44b1a3c44b23e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733710440,
      "headline": "Apple Tops the List of Best-Managed Companies of 2024",
      "id": 131864915,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Tech companies hold six of the top 10 spots, while Mastercard jumped to fifth place from 24th last year.",
      "url": "https://finnhub.io/api/news?id=d13cca814be7a6fe4ddcc7139ff6790f37d3900f98cf04b25ea44b1a3c44b23e"
    }
  },
  {
    "ts": null,
    "headline": "DARZALEX FASPRO速 (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO速 (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2 These findings were demonstrated in an expanded MRD analysis of the Phase 3 CEPHEUS study (Abstract #362) and a post hoc analysis of clinically relevant s",
    "url": "https://finnhub.io/api/news?id=039efc3058d0f75ab21571e38f6437033edc7ce374fdbd913827f7a11ad50a5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733704200,
      "headline": "DARZALEX FASPRO速 (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma",
      "id": 131865434,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO速 (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2 These findings were demonstrated in an expanded MRD analysis of the Phase 3 CEPHEUS study (Abstract #362) and a post hoc analysis of clinically relevant s",
      "url": "https://finnhub.io/api/news?id=039efc3058d0f75ab21571e38f6437033edc7ce374fdbd913827f7a11ad50a5c"
    }
  }
]